Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 12/12/25 → 12/12/27 |
Funding
- Bristol Myers Squibb Company: $2.00
25-GU-91-BMS (CA2440012): A Randomized, Open-label, Phase 2/3 Trial of Izalontamab Brengitecan Versus Platinum-Based Chemotherapy for Metastatic Urothelial Cancer in Participants with Disease Progression on or After an Immunotherapy-Based Treatment
- Myint, Zin (PI)